Current state · 2026.
The 2026 stack is roughly 90% converged on ICH M9 biowaiver scope and the 80–125% bound, with persistent operational divergence in HV drug scaling, NTI lists, and reference product sourcing.
Current state · 2026.
Live now · in transitionThe 2026 stack is roughly 90% converged on ICH M9 biowaiver scope and the 80–125% bound, with persistent operational divergence in HV drug scaling, NTI lists, and reference product sourcing. What is live, what is moving:
Standard BE bound universal.
80.00–125.00% (90% CI, log-transformed AUC + Cmax) across FDA, EMA, ANVISA, WHO. Schuirmann TOST is the global default statistical method.
HV drug scaling divergence.
FDA: RSABE on AUC + Cmax (up to 69.84–143.19%). EMA: Cmax only, AUC standard 80–125%. ANVISA: EMA-aligned. A US-designed RSABE study must still meet EMA's AUC standard at EU filing.
NTI drug lists divergent.
FDA list longest (warfarin, digoxin, levothyroxine, lithium, theophylline, phenytoin, carbamazepine, cyclosporine, tacrolimus, sirolimus). EMA shortest. ANVISA most explicitly codified (RDC 742/2022). Sponsors must reverify per jurisdiction.
BCS biowaiver convergence.
Post-M9: Class I universally accepted (very rapid dissolution ≥85% in 15 min); Class III accepted with stricter excipient and dissolution criteria. Class II/IV not eligible universally.
Reference product sourcing.
FDA: US RLD, foreign-sourced generally not accepted. EMA: EU-sourced with bridging for non-EU. ANVISA: strictly locally registered Brazilian innovator (changed 2022, non-negotiable). WHO PQ: flexible to source-country.
Biosimilar PK BE distinct.
Same TOST machinery (80–125%) but a totality-of-evidence framework: analytical similarity → PK similarity → comparative efficacy. Immunogenicity (ADA assays) in parallel. Distinct rules in FDA 351(k), EMA biosimilar guideline, ANVISA RDC 55/2010.
Biosimilar interchangeability.
FDA: formal "interchangeable" designation under BPCI Act 2009 (requires switching studies). EMA: no federal designation, member states decide. ANVISA: no formal designation (2026).
ANVISA Rules 2024 operational.
Healthy-volunteer registry mandatory (prevents professional-volunteer cross-contamination); genotoxic impurity record for BE clinical batch mandatory (stricter than FDA/EMA); updated NTI list; Brazilian reference product non-negotiable.
Virtual BE / PBPK trajectory.
FDA 2024 MIDD guidance permits PBPK as supportive for biowaivers, food-effect waiver, dose-proportionality. Full primary-evidence acceptance for selected complex generics projected 2030–2035. EMA 2025 reflection paper cautious.
Global 2026 stack.
Design AUC to standard 80–125% (captures all regulators); scale Cmax under EMA/ANVISA logic (covers FDA as subset); source reference product carefully per jurisdiction; plan ANVISA volunteer registry compliance; document genotoxic impurity for BE clinical batch.